Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**MenACWY vaccine** is a nonproprietary category of quadrivalent meningococcal vaccines intended to induce active immunity against *Neisseria meningitidis* serogroups A, C, W, and Y. The supplied trial context identifies MenACWY only as one of several vaccines administered to iron-deficient Kenyan women to evaluate how oral iron timing affects vaccine immune responses; it does not identify a specific licensed MenACWY product, manufacturer, formulation, or antigen-carrier composition. Nicole Stoffel is associated with the study context, not established as the developer of a distinct MenACWY vaccine asset. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05919472))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MenACWY vaccine-Nicole Stoffel-iron deficiency anemia.